Fredun Pharmaceuticals Limited Stock Price Today (NSE: FREDUN)
Fundamental Score
Fredun Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Fredun Pharmaceuticals Limited share price today is ₹1221.60, down 8.01% on NSE/BSE as of 16 September 2026. Fredun Pharmaceuticals Limited (FREDUN) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.56K (Cr). The 52-week high for FREDUN share price is ₹1590.00 and the 52-week low is ₹1195.20. At a P/E ratio of 46.92x, FREDUN is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 15.81% and a debt-to-equity ratio of 0.80.
Fredun Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Fredun Pharmaceuticals Limited share price chart: 18.16% return over the past month. 52-week high ₹1590.00, 52-week low ₹1195.20.
Fredun Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1322.50 | ₹1345.80 | ₹1195.20 | ₹1221.60 | 3.07L (Cr) | |
| ₹1424.70 | ₹1424.70 | ₹1308.10 | ₹1327.90 | 66.07K (Cr) | |
| ₹1450.00 | ₹1450.00 | ₹1400.00 | ₹1412.20 | 25.21K (Cr) | |
| ₹1460.00 | ₹1493.00 | ₹1418.20 | ₹1461.20 | 44.07K (Cr) | |
| ₹1369.30 | ₹1449.00 | ₹1348.00 | ₹1439.20 | 63.59K (Cr) | |
| ₹1409.90 | ₹1430.00 | ₹1320.10 | ₹1356.80 | 97.27K (Cr) | |
| ₹1487.00 | ₹1487.00 | ₹1360.00 | ₹1405.50 | 33.12K (Cr) | |
| ₹1502.90 | ₹1517.00 | ₹1458.00 | ₹1470.70 | 15.10K (Cr) | |
| ₹1525.90 | ₹1525.90 | ₹1480.00 | ₹1488.30 | 9.56K (Cr) | |
| ₹1497.80 | ₹1519.60 | ₹1470.00 | ₹1505.80 | 9.71K (Cr) |
Fredun Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1463.70 | ₹1531.00 | ₹1195.20 | ₹1221.60 | -16.54% | |
| ₹997.00 | ₹1599.90 | ₹990.10 | ₹1446.90 | +45.13% | |
| ₹2790.00 | ₹2950.00 | ₹851.70 | ₹987.00 | -64.62% | |
| ₹2490.00 | ₹2825.00 | ₹2199.35 | ₹2814.30 | +13.02% | |
| ₹2240.10 | ₹2620.00 | ₹2164.95 | ₹2495.55 | +11.40% | |
| ₹1667.20 | ₹2278.85 | ₹1667.20 | ₹2230.90 | +33.81% | |
| ₹1515.15 | ₹1840.00 | ₹1452.50 | ₹1671.80 | +10.34% | |
| ₹1560.00 | ₹1944.00 | ₹1508.00 | ₹1624.45 | +4.13% | |
| ₹1570.00 | ₹1627.00 | ₹1362.15 | ₹1538.30 | -2.02% | |
| ₹1979.95 | ₹1999.00 | ₹1502.30 | ₹1578.30 | -20.29% | |
| ₹1476.00 | ₹1971.25 | ₹1471.10 | ₹1923.45 | +30.32% | |
| ₹1346.00 | ₹1785.00 | ₹1281.00 | ₹1539.15 | +14.35% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Fredun Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Fredun Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of FREDUN across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (15.81%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.49%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Robust Profit Growth (56.58%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (27.26%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (36.54% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (64.50% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (75.23% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 46.92x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Interest Coverage (2.21x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-122.53 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 3.87%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Fredun Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Fredun Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Fredun Pharmaceuticals LimitedFredun Pharmace...Selected✓ FREDUN • 539730 | 66.8/100 | ₹1221.60₹1222 | ₹1558.22₹1558.22 | 46.92Average 46.9 Average | 15.81%Good 15.81% Good | 21.49%Excellent 21.49% Excellent | 0.80Good 0.8 Good | 75.23%Excellent 75.23% Excellent | 36.54%Excellent 36.54% Excellent | 0.01% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1851.80₹1852 | ₹444302.37₹444302.37 | 36.74Average 36.7 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9421.00₹9421 | ₹249656.50₹249656.50 | 85.48Average 85.5 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4948.00₹4948 | ₹167470.01₹167470.01 | 79.04Average 79.0 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1124.20₹1124 | ₹112195.16₹112195.16 | 25.05Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1372.20₹1372 | ₹110853.17₹110853.17 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.00₹1941 | ₹104862.52₹104862.52 | 95.80Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1670.20₹1670 | ₹96103.31₹96103.31 | 26.10Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1136.80₹1137 | ₹94922.80₹94922.80 | 29.38Average 29.4 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2071.50₹2072 | ₹94719.34₹94719.34 | 17.12Average 17.1 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2259.00₹2259 | ₹93296.70₹93296.70 | 45.65Average 45.6 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price444302.37 Cr
- Divi's Laboratories Limited share price249656.50 Cr
- Torrent Pharmaceuticals Limited share price167470.01 Cr
- Zydus Lifesciences Limited share price112195.16 Cr
- Cipla Limited share price110853.17 Cr
Fredun Pharmaceuticals Limited PE Ratio History
Historical price-to-earnings ratio for FREDUN — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹44.83 | ₹1578.30 | 35.2x |
| FY 2024 | ₹33.32 | ₹737.25 | 22.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Fredun Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for FREDUN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
27.26%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
56.58%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
36.54%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
75.23%
Compounded annual net profit growth over 5 years
Fredun Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for FREDUN — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Fredun Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Fredun Pharmaceuticals Limited (FREDUN) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Fredun Pharmaceuticals Limited
About FREDUN (Fredun Pharmaceuticals Limited)
Fredun Pharmaceuticals Ltd is a globally-minded pharmaceutical company dedicated to improving health outcomes through the development, manufacturing, and distribution of a diverse ...range of healthcare products. With a firm commitment to innovation and quality, FREDUN operates at the intersection of science and wellness, offering effective solutions to address a spectrum of medical needs. The company's reach extends across continents, delivering essential medicines and health support to underserved communities and established markets alike. By prioritizing research and development and adhering to stringent international standards, FREDUN aims to be a trusted partner in healthcare, empowering individuals to live healthier and more fulfilling lives. FREDUN's product portfolio spans across a broad spectrum of therapeutic categories, including both prescription and over-the-counter medications, as well as specialized dietary supplements and nutraceuticals. The company meticulously crafts its formulations using advanced technologies and rigorously tested ingredients to ensure optimal efficacy and safety. From addressing common ailments to managing chronic conditions, FREDUN provides reliable and accessible healthcare options for a variety of patient needs. Committed to accessibility and affordability, FREDUN strives to bridge the gap between cutting-edge pharmaceutical advancements and the needs of diverse populations around the world. Beyond manufacturing and distributing pharmaceutical products, FREDUN is dedicated to fostering long-term health improvements through educational initiatives and community engagement. By partnering with healthcare professionals and organizations, the company seeks to promote awareness about preventative care and disease management, empowering individuals to take proactive steps towards a healthier lifestyle. FREDUN is deeply invested in sustainable practices and ethical operations, striving to minimize its environmental footprint and contribute positively to the communities it serves. The company envisions a future where quality healthcare is accessible to all, and it is dedicated to working tirelessly to make that vision a reality.
Company Details
Key Leadership
FREDUN Share Price: Frequently Asked Questions
What is the current share price of Fredun Pharmaceuticals Limited?
Fredun Pharmaceuticals Limited (FREDUN) trades at ₹1221.60 on NSE and BSE. Market cap ₹1.56K (Cr). Educational data only.
What is the P/E ratio of Fredun Pharmaceuticals Limited?
Fredun Pharmaceuticals Limited has a P/E of 46.92x vs industry average 34.89x.
What is the Bull Run score for Fredun Pharmaceuticals Limited?
Fredun Pharmaceuticals Limited has a Bull Run score of 66.8/100 based on 25+ financial parameters.
Does Fredun Pharmaceuticals Limited pay dividends?
Fredun Pharmaceuticals Limited has a dividend yield of 0.01%. Past dividends don't guarantee future payments.
What is the ROE of Fredun Pharmaceuticals Limited?
Fredun Pharmaceuticals Limited has ROE of 15.81%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Fredun Pharmaceuticals Limited?
Fredun Pharmaceuticals Limited has debt-to-equity of 0.80.
Is Fredun Pharmaceuticals Limited a good investment?
Bull Run gives Fredun Pharmaceuticals Limited a score of 66.8/100. This is not investment advice — consult a SEBI-registered advisor.